There is significant evidence for a role of RAS and JAK/STAT pathway activation in HCC and therapeutic modulation of these pathways for the treatment of human liver cancer is being actively explored (Calvisi et al, 2006). The gene discussed is SOAT1; the disease is liver cancer.